Source: Health Products Regulatory Authority (IE) Revision Year: 2021 Publisher: GlaxoSmithKline Consumer Healthcare (Ireland) Limited, 12 Riverwalk, Citywest Business Campus, Dublin 24, Ireland
Otrivine Adult Menthol 0.1% w/v Nasal Spray, Solution.
| Pharmaceutical Form |
|---|
|
Nasal spray, solution (nasal spray). Colourless to whitish, clear to opalescent nasal spray solution with an odour of menthol and eucalyptus. |
Xylometazoline Hydrochloride 0.1% w/v.
Excipients: Benzalkonium chloride 0.01% w/v.
For a full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Xylometazoline |
Xylometazoline acts directly on α-adrenoreceptors but does not act on β-receptors. When used topically as a nasal decongestant, xylometazoline acts rapidly and provides long-lasting relief. Onset of action is within minutes, the decongestant effect being prolonged and lasting for up to 10 hours. |
| List of Excipients |
|---|
|
Benzalkonium chloride |
Squeeze bottle of high density polyethylene and polypropylene, with polyethylene nose piece.
Pack size: 10ml.
GlaxoSmithKline Consumer Healthcare (Ireland) Limited, 12 Riverwalk, Citywest Business Campus, Dublin 24, Ireland
PA0678/120/004
Date of first authorisation: 13 July 1998
Date of last renewal: 24 May 2009
| Drug | Countries | |
|---|---|---|
| OTRIVIN | Austria, Canada, Cyprus, Estonia, Finland, Hong Kong, Israel, Lithuania, Malta, Nigeria, Netherlands, New Zealand, Poland, Singapore, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
